Novartis AG NVS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 55.38B | 54.77B | 54.41B | 54.53B | 54.35B |
| Total Other Revenue | 1.99B | 1.93B | 2.17B | 2.14B | 2.02B |
| Total Revenue | 57.36B | 56.69B | 56.58B | 56.67B | 56.37B |
| Cost of Revenue | 14.23B | 14.20B | 13.84B | 13.63B | 13.40B |
| Gross Profit | 43.13B | 42.50B | 42.74B | 43.04B | 42.97B |
| SG&A Expenses | 12.88B | 13.11B | 13.32B | 13.24B | 13.31B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 609.00M | 496.00M | 703.00M | 926.00M | -154.00M |
| Total Operating Expenses | 39.06B | 39.11B | 39.16B | 38.67B | 36.92B |
| Operating Income | 18.30B | 17.58B | 17.42B | 18.00B | 19.45B |
| Income Before Tax | 12.64B | 15.52B | 15.78B | 16.35B | 16.42B |
| Income Tax Expenses | 2.63B | 2.78B | 2.27B | 2.39B | 2.04B |
| Earnings from Continuing Operations | 10.01K | 12.75K | 13.51K | 13.97K | 14.38K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 18.00M | 10.00M | 20.00M | 17.00M | 10.00M |
| Net Income | 10.03B | 12.76B | 13.53B | 13.98B | 14.39B |
| EBIT | 18.30B | 17.58B | 17.42B | 18.00B | 19.45B |
| EBITDA | 22.88B | 22.11B | 21.92B | 22.47B | 23.92B |
| EPS Basic | 5.26 | 6.67 | 7.03 | 7.21 | 7.36 |
| Normalized Basic EPS | 5.48 | 5.27 | 5.23 | 5.40 | 5.92 |
| EPS Diluted | 5.24 | 6.63 | 6.98 | 7.15 | 7.31 |
| Normalized Diluted EPS | 5.45 | 5.24 | 5.20 | 5.37 | 5.88 |
| Average Basic Shares Outstanding | 7.62B | 7.65B | 7.70B | 7.76B | 7.83B |
| Average Diluted Shares Outstanding | 7.66B | 7.70B | 7.75B | 7.81B | 7.88B |
| Dividend Per Share | 4.67 | 4.67 | 4.67 | 4.67 | 3.86 |
| Payout Ratio | 90.40% | 71.08% | 64.15% | 55.91% | 54.32% |